Home / Pfizer INC (PFE) / utomilumab
Forward catalyst · PFE

utomilumab

Sponsor Pfizer INC · listed as PFE

READOUT Phase 3 Confidence: medium Source: clinicaltrials

Next catalyst

Event typeREADOUT
Expected date2026-12-31
As disclosedDec 31, 2026
Date precisionday
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT05059522
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorPfizer
Listed asPFE
Condition(s)Advanced Malignancies; NSCLC; Ovarian Cancer; Urothelial Cancer; Solid Tumors
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 →   More PFE catalysts